AAP Update Guidance on RSV Treatment for Children

The American Academy of Pediatrics has issued updated guidance addressing children at high risk of complications from respiratory syncytial virus as well as providing eligible infants with more than five consecutive doses of palivizumab in regions where there is widespread and intense RSV circulation.

"Given this information, together with the known efficacy of palivizumab and unpredictable epidemiology of RSV since the summer of 2021, the AAP recommends programmatic consideration of providing more than 5 consecutive doses of palivizumab depending on the duration of the current RSV surge in a given region of the country," according to the guidance. 

Read the full updated guidance here.